NANONEWRON LLC

Biotech · Private

Humanized TNFα inhibitor molecules designed to cross the blood-brain barrier for Alzheimer's disease treatment

Grants
$3.0M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Discovery of therapeutic nanobodies targeting brain TNF-α for the treatment of Alzheimer Disease$499,828
Federal grantDepartment of Health and Human Services · Phase II · Development of a therapeutic nanobody targeting brain TNFa for the treatment of Alzheimer Disease$979,592
Federal grantDepartment of Health and Human Services · Phase II · Development of a therapeutic nanobody targeting brain TNFa for the treatment of Alzheimer Disease$1,519,969
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3053Pharmareview Corporation——
3054BIOSETTIA, INC.——
3055VEANA THERAPEUTICS LLC——
3056NANONEWRON LLC——
3057CatalYm——
3058TFC BIOSCIENCES, INC.——
3059NEOCHROMOSOME, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.